Clinical Trial Search

Primary: Total Number of Adverse Events — 7; 7; 3; 7 Number of Adverse Events

Primary: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment — 71.4…

Primary: Percentage of Participants With Greater Than or Equal to (>=) 50 Percent (%) Reduction in Prostate-Specific Antigen (PSA) During the Core Study — 86.9 Percentage of…

Primary: Pain at Hour 4 — 4.2; 4.1 units on a scale — p=0.82

Primary: Percentage of Subjects Who Agreed to Participated in the Esophageal Assessment — 40.7; 45.7; 47.5 percentage of participants — p=0.25

Primary: Percentage of Participants With a Minimal Residual Disease (MRD) Response Within 4 Cycles of Treatment — 80.0 percentage of participants — p=0.0000

Primary: Total Number of Adverse Events — 9; 15; 5; 12 Total Number of AE

Primary: Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Percent (%) Improvement (ACR20 Response) at Week 24 — 86 percentage of participants

Primary: Incidence of Participants Who Experienced at Least One Adverse Event — 17 Participants

Primary: Number of Participants With a Response of CR, CRp, or PR — 0; 1; 0 participants

Primary: Pregnancy Success Rate — 75; 25 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment — 97.4 Percentage of participants

Primary: Number of Participants With Adverse Events (AEs) — 67; 36; 71; 68 participants

Primary: Incidence Rate of New Digital Ulcers (DUs) up to Week 16 — 0.9082; 0.9567; 0.8115 number of new DUs/observation days — p=0.706

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses — 97.0; 90.2 percentage of participants